Hodgkin Lymphoma – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H1 2012', provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. 'Hodgkin Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hodgkin Lymphoma.
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Hodgkin Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hodgkin Lymphoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Hodgkin Lymphoma 12
Hodgkin Lymphoma Therapeutics under Development by Companies 14
Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Hodgkin Lymphoma Therapeutics – Products under Development by Companies 27
Hodgkin Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 30
Companies Involved in Hodgkin Lymphoma Therapeutics Development 42
Bristol-Myers Squibb Company 42
Genzyme Corporation 43
Sanofi-Aventis 44
Seattle Genetics, Inc. 45
Gilead Sciences, Inc. 46
Daiichi Sankyo Company, Ltd 47
Merck & Co., Inc. 48
Gamida Cell Ltd. 49
Celltrion, Inc. 50
ZIOPHARM Oncology, Inc. 51
Novartis AG 52
Cephalon, Inc. 53
4SC AG 54
Hana Biosciences, Inc. 55
MethylGene Inc 56
Keryx Biopharmaceuticals, Inc. 57
Allos Therapeutics, Inc 58
Cytokinetics, Inc 59
Pharmacyclics, Inc. 60
Digna Biotech, S.L. 61
Affimed Therapeutics AG 62
Philogen S.p.A. 63
S*BIO Pte Ltd 64
Syndax Pharmaceuticals, Inc. 65
Xencor, Inc. 66
Aprea AB. 67
Archer Biosciences, Inc 68
Hodgkin Lymphoma – Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Route of Administration 71
Assessment by Molecule Type 74
Drug Profiles 77
StemEx - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Adcetris - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Adcetris - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
LBH589 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Adriamycin + Bleomycin + Vincristine + Dacarbazine + Radiation Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisone + Vincristine Sulfate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 88
Filgrastim + Cisplatin + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide Phosphate + Ifosfamide + Prednisone + Vincristine Sulfate + Vinorelbine Ditartrate + Radiation Therapy - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
Adriamycin + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Etoposide + Methylprednisolone + Vincristine Sulfate + Vindesine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 93
Carmustine + Cisplatin + Cytarabine + Dexamethasone + Adiramycin + Etoposide + Gemcitabine Hydrochloride + Ifosfamide + Melphalan + Methylprednisolone + Mitoguazone + Vindesine + Vinorelbine Ditartrate + Allogeneic Stem Cell Transplantation + Autologous Stem Cell Transplantation - Drug Profile 94
Product Description 94
Mechanism of Action 95
R&D Progress 96
Adriamycin + Bleomycin + Vinblastine + Dacarbazine - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Bleomycin + Etoposide + Doxorubicin + Cyclophosphamide + Vincristine + Procarbazine + Prednisone + Goserelin - Drug Profile 99
Product Description 99
Mechanism of Action 100
R&D Progress 101
Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Prednisone + Vincristine + Doxorubicin Hydrochloride + Etoposide - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 107
Prednisone + Vincristine + Doxorubicin Hydrochloride + Etoposide + Procarbazine Hydrochloride + Cyclophosphamide - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 109
Prednisone + Vincristine + Doxorubicin Hydrochloride + Etoposide + Dacarbazine + Cyclophosphamide - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 112
Ifosfamide + Etoposide + Prednisone + Doxorubicin hydrochloride + Bleomycin + Vinblastine + Dacarbazine + Radiation therapy - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 115
Ifosfamide + Etoposide + Prednisone + Doxorubicin Hydrochloride + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Radiation Threapy + Stem Cell Transplantation - Drug Profile 117
Product Description 117
Mechanism of Action 118
R&D Progress 118
ABVD Regimen + Carmustine + Etoposide + Cyclophosphamide + Stem Cell Transplantation - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 121
Prednisone + Predinosolone + Vincristine + Doxorubicin + Etoposide + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 123
Product Description 123
Mechanism of Action 124
R&D Progress 124
Prednisone/Predinosolone + Vincristine + Doxorubicin + Etoposide + Procarbazine Hydrochloride + Cyclophosphamide + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 127
Product Description 127
Mechanism of Action 128
R&D Progress 129
Prednisone + Predinosolone + Vincristine + Doxorubicin + Etoposide + Cyclophosphamide + Dacarbazine + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 131
Product Description 131
Mechanism of Action 132
R&D Progress 133
Filgrastim + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Methotrexate + Vincristine Sulfate - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 136
Filgrastim + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Methotrexate + Vincristine Sulfate - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 139
Ifosfamide + Amsacrine + Etoposide - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Bleomycin Sulfate + ABVD Regimen + Dacarbazine + Doxorubicin Hydrochloride + Vinblastine + Radiation Therapy - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 142
Adriamycin + Bleomycin + Vinblastine + Etoposide + Procarbazine + Prednisone + Vincristine + Radiation Therapy - Drug Profile 143
Product Description 143
Mechanism of Action 144
R&D Progress 144
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Prednisone + Vincristine Sulfate + Vinorelbine Ditartrate - Drug Profile 145
Product Description 145
Mechanism of Action 146
R&D Progress 147
Rituximab + ABVD Regimen - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 149
Bleomycin Sulfate + Filgrastim + Cyclophosphamide + Dacarbazine + Doxorubicin Hydrochloride + Etoposide + Prednisone + Procarbazine Hydrochloride + Vinblastine + Vincristine Sulfate - Drug Profile 150
Product Description 150
Mechanism of Action 151
R&D Progress 152
Bleomycin Sulfate + Filgrastim + Pegfilgrastim + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisolone + Procarbazine Hydrochloride + Vincristine Sulfate - Drug Profile 154
Product Description 154
Mechanism of Action 155
R&D Progress 156
Bleomycin Sulfate + ABVD Regimen + Carmustine + Cyclophosphamide + Dacarbazine + Doxorubicin Hydrochloride + Etoposide + Vinblastine - Drug Profile 157
Product Description 157
Mechanism of Action 158
R&D Progress 158
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisolone + Vincristine Sulfate - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 161
Bleomycin Sulfate + Filgrastim + Dexrazoxane Hydrochloride + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate + Radiation Therapy - Drug Profile 163
Product Description 163
Mechanism of Action 164
R&D Progress 164
ABVD - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
BEACOPP + Radiotherapy - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 169
Hodgkin Lymphoma Therapeutics – Drug Profile Updates 171
Hodgkin Lymphoma Therapeutics – Discontinued Products 182
Hodgkin Lymphoma Therapeutics - Dormant Products 184
Hodgkin Lymphoma – Product Development Milestones 190
Featured News & Press Releases 190
Jan 13, 2012: Seattle Genetics Announces Updates To ADCETRIS's Prescribing Information 190
Dec 13, 2011: Keryx Biopharmaceuticals Presents Phase II Data Of KRX-0401 In Hodgkin's Lymphoma At ASH Meeting 191
Dec 12, 2011: Seattle Genetics Reports Data From Multiple Presentations On ADCETRIS At ASH Annual Meeting 192
Dec 12, 2011: Aeterna Zentaris Reported Encouraging Preclinical Data For Perifosine In Hodgkin Lymphoma At ASH Meeting 193
Dec 11, 2011: Syndax's Entinostat Demonstrates Activity In Hodgkin's Lymphoma 195
Dec 08, 2011: Stemline Therapeutics Announces Two Poster Presentations Of SL-401 Efficacy Data Against Lymphoid Cancers At 53rd Annual Meeting Of American Society Of Hematology 196
Dec 07, 2011: 4SC Obtains Key Patent For Resminostat In Japan 197
Dec 06, 2011: 4SC To Present Clinical Development Program With Resminostat At World Epigenetics Summit 198
Dec 05, 2011: Aeterna Zentaris To Present Data On Perifosine At Upcoming ASH Meeting In San Diego, California 198
Dec 05, 2011: Keryx Announces Upcoming Presentation On KRX-0401 At 53rd Annual Meeting Of American Society Of Hematology 199
Appendix 200
Methodology 200
Coverage 200
Secondary Research 200
Primary Research 200
Expert Panel Validation 201
Contact Us 201
Disclaimer 201
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Hodgkin Lymphoma, H1 2012 12
Products under Development for Hodgkin Lymphoma – Comparative Analysis, H1 2012 13
Number of Products under Development by Companies, H1 2012 15
Number of Products under Development by Companies, H1 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 22
Comparative Analysis by Late Stage Development, H1 2012 23
Comparative Analysis by Mid Clinical Stage Development, H1 2012 24
Comparative Analysis by Early Clinical Stage Development, H1 2012 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 26
Products under Development by Companies, H1 2012 27
Products under Development by Companies, H1 2012 (Contd..1) 28
Products under Development by Companies, H1 2012 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2012 30
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 41
Bristol-Myers Squibb Company, H1 2012 42
Genzyme Corporation, H1 2012 43
Sanofi-Aventis, H1 2012 44
Seattle Genetics, Inc., H1 2012 45
Gilead Sciences, Inc., H1 2012 46
Daiichi Sankyo Company, Ltd, H1 2012 47
Merck & Co., Inc., H1 2012 48
Gamida Cell Ltd., H1 2012 49
Celltrion, Inc., H1 2012 50
ZIOPHARM Oncology, Inc., H1 2012 51
Novartis AG, H1 2012 52
Cephalon, Inc., H1 2012 53
4SC AG, H1 2012 54
Hana Biosciences, Inc., H1 2012 55
MethylGene Inc, H1 2012 56
Keryx Biopharmaceuticals, Inc., H1 2012 57
Allos Therapeutics, Inc, H1 2012 58
Cytokinetics, Inc, H1 2012 59
Pharmacyclics, Inc., H1 2012 60
Digna Biotech, S.L., H1 2012 61
Affimed Therapeutics AG, H1 2012 62
Philogen S.p.A., H1 2012 63
S*BIO Pte Ltd, H1 2012 64
Syndax Pharmaceuticals, Inc., H1 2012 65
Xencor, Inc., H1 2012 66
Aprea AB., H1 2012 67
Archer Biosciences, Inc, H1 2012 68
Assessment by Monotherapy Products, H1 2012 69
Assessment by Combination Products, H1 2012 70
Assessment by Stage and Route of Administration, H1 2012 73
Assessment by Molecule Type, H1 2012 76
Hodgkin Lymphoma Therapeutics – Drug Profile Updates 171
Hodgkin Lymphoma Therapeutics – Discontinued Products 182
Hodgkin Lymphoma Therapeutics – Discontinued Products (Contd..1) 183
Hodgkin Lymphoma Therapeutics – Dormant Products 184
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..1) 185
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..2) 186
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..3) 187
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..4) 188
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..5) 189
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2012 12
Products under Development for Hodgkin Lymphoma – Comparative Analysis, H1 2012 13
Products under Development by Companies, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 17
Late Stage Products, H1 2012 23
Mid Clinical Stage Products, H1 2012 24
Early Clinical Stage Products, H1 2012 25
Discovery and Pre-Clinical Stage Products, H1 2012 26
Assessment by Monotherapy Products, H1 2012 69
Assessment by Combination Products, H1 2012 70
Assessment by Route of Administration, H1 2012 71
Assessment by Stage and Route of Administration, H1 2012 72
Assessment by Molecule Type, H1 2012 74
Assessment by Stage and Molecule Type, H1 2012 75
[Tabellenverzeichnis ausblenden]